Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Fusion Pharmaceuticals Inc

Current price
Last closed 21.55 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 833 042 944 USD
Yield for 12 month -100.00 %
21.11.2021 - 28.11.2021

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. As of June 4, 2024, Fusion Pharmaceuticals Inc. operates as a subsidiary of AstraZeneca AB. Address: 270 Longwood Road South, Hamilton, ON, Canada, L8P 0A6

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

21.14 USD

P/E ratio

Dividend Yield

Current Year

+2 068 000 USD

Last Year

+1 461 000 USD

Current Quarter

Last Quarter

+33 636 000 USD

Current Year

+723 000 USD

Last Year

-57 434 000 USD

Current Quarter

-361 000 USD

Last Quarter

+33 275 000 USD

Key Figures FUSN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -108 804 000 USD
Operating Margin TTM -5403.78 %
PE Ratio
Return On Assets TTM -23.34 %
PEG Ratio
Return On Equity TTM -47.11 %
Wall Street Target Price 21.14 USD
Revenue TTM 2 040 000 USD
Book Value 2.85 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -57 434 000 USD
Earnings per share -1.4 USD
Diluted Eps TTM -1.4 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics FUSN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FUSN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FUSN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 785.8779
Price Sales TTM 874.5034
Enterprise Value EBITDA -18.5527
Price Book MRQ 8.1287

Financials FUSN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FUSN

For 52 weeks

2.31 USD 21.6 USD
50 Day MA 21.4 USD
Shares Short Prior Month 3 947 961
200 Day MA 10.83 USD
Short Ratio 6.22
Shares Short 3 060 451
Short Percent 4.22 %

Dynamics of changes in the value of assets




446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds



203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics



2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics